Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Genoptix, Inc. (“Genoptix” or the “Company”) (Nasdaq: GXDX) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Novartis in a transaction with an approximate total equity value of $470 million. Click here to learn how to join the action: http://www.rigrodskylong.com/news/GenoptixInc-GXDX.

Under the proposed agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25.00 per share. Additionally, each of Genoptix’ directors and executive officers has agreed to tender their shares in the offer.

The investigation concerns whether Genoptix’ board of directors failed to adequately shop the Company and obtain the best price possible for Genoptix’ shareholders before entering into the agreement with Novartis. Indeed, according to Yahoo! Finance, at least one analyst has set a $28.00 per share price target for Genoptix stock.

If you own the common stock of Genoptix and purchased your shares before January 24, 2011, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Grafico Azioni Genoptix, Inc. (MM) (NASDAQ:GXDX)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Genoptix, Inc. (MM)
Grafico Azioni Genoptix, Inc. (MM) (NASDAQ:GXDX)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Genoptix, Inc. (MM)